Pharmacology
Doxorubicin hydrochloride used to treat some leukemias and Hodgkin's lymphoma.
Efficacy
| Animal Model | Administration | Dosage | Formulation | Description |
|---|---|---|---|---|
| SKOV-3 human ovarian tumor xenograft mice model[1] | i.p. | 20 mg/kg | / | Doxorubicin significantly increases the lipid peroxide level in non-transgenic normal mouse hearts |
| Adult male ICR mice[2] | i.p. | 20 mg/kg | / | Doxorubicin treatment results in significant reductions of end-diastolic dimension and stroke volume |
| Female MF1 nude mice[3] | i.v. | 8 mg/kg | saline | Doxorubicincauses statistically significant inhibition of tumor growth |
| spontaneouslyhypertensiverats (SHR)[4] | i.p. | 12 mg/kg | / | doxorubicin induced significant toxicity in the heart, kidneys and intestine |
| male and femalerats[5] | i.p. | 10 mg/kg | saline | Doxorubicin induces apoptosis |
Pharmacokinetics and Pharmacodynamics
To be updated
Toxicity
To be updated
References
[1] Kang YJ, et al. J BiolChem, 1996, 271(21), 12610-12616.
[2] Weinstein DM, et al. J PharmacolExpTher, 2000, 294(1), 396-401.
[3]Ottewell PD, et al. J NatlCancerInst, 2008, 100(16), 1167-1178.
[4]Zhang J, et al. J Mol Cell Cardiol, 1996, 28(9), 1931-1943.
[5]Jang YM, et al. FEBS Lett, 2004, 577(3), 483-490.
